Gimv, established in 1980, is a Belgian-based investment company specializing in private equity and venture capital. With over 40 years of experience, Gimv manages a portfolio of 85 companies across Europe, generating a combined turnover of over EUR 6 billion and employing more than 28,000 professionals. The company focuses on business-to-business, financial services, healthcare, information technology, and other sectors, with a majority (75%) of its investments in private equity.
Managing Partner - Head Sustainable Cities and Member of the Executive Committee
Maja Markovic
Principal
Nick Medaer
Partner
Stephane Mircich
Principal
Ruben Monballieu
Partner
David De Peuter
Senior Principal, Consumer
Rombout Poos
Finance Director and Business Analyst
Christophe Van Quickenborne
Partner
Morgane Renault
Principal, Consumer
Tom Roth
Associate, Connected Consumer
Elsa Spangenberg
Associate, Healthcare
Eline Talboom
Business analyst
Lars Timmer
Senior Principal, Healthcare
Muriel Uytterhaegen
Principal, Smart Industries
Bram Vanparys
Partner
Eric de La Vigne
Principal
Michaël Vlemmix
Partner, Life Sciences
Tom Voorde
Managing Partner - Head of Smart Industries and member of Investment Committee
Kalle Wanner
Principal, Sustainable Cities
Boris Wirtz
Principal
Nicolas de Saint Laon
Partner
220 past transactions
The Spice Factory
Acquisition in 2025
The Spice Factory is a manufacturer of herbs and spices, catering to customers in Belgium, France, the United Kingdom, and the Netherlands. The company specializes in producing a wide range of herbs, spices, and seasonings, serving both large retailers and food service industries. It offers products under private labels for various brands, as well as its own brand offerings, ensuring a diverse selection to meet the needs of different market segments.
Fire1
Venture Round in 2025
Fire1, based in Dublin, Ireland, is dedicated to developing innovative therapeutic devices aimed at enhancing the lives of heart failure patients. The company has created a remote monitoring system that allows healthcare providers to access real-time patient data and insights. This technology facilitates the early detection of complications associated with heart failure, enabling proactive interventions that can lead to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to address critical challenges in heart failure management and contribute to better healthcare solutions.
Tibbloc
Acquisition in 2024
Tibbloc specializes in providing turnkey rental solutions for heating, air conditioning, cooling, and related services. Founded in 2007 and headquartered in Saint-Julien-de-Concelles, France, the company operates additional offices in key cities including Paris, Lyon, Nantes, Lille, and Marseille. Tibbloc caters to various sectors, including facility management, engineering, food and beverage, and manufacturing. Its offerings encompass project studies, maintenance, transport and unloading, on-site installation and commissioning, as well as fuel supply and management. The company also provides emergency management services and customizable service options tailored to meet clients' specific technical requirements and budgetary constraints.
Lupine
Acquisition in 2024
Lupine is a company that offers repair services. They change the product in any way but reduce the impact on the environment caused by waste and, at the same time, protect wallet. They develop and produce lamps. The lamp includes all relevant components and the completed repair letter in a package.
Kivu Biosciences
Series A in 2024
Kivu Bioscience is a biotech company developing next-generation antibody-drug conjugates to deliver best-in-class therapeutics and focused on rapidly advancing next generation transformative assets.
ImmunOs Therapeutics
Series C in 2024
ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of novel human immunomodulatory proteins aimed at enhancing cancer treatment and addressing autoimmune diseases. By focusing on next-generation therapeutics, ImmunOs aims to create drugs that not only exhibit direct anti-tumor effects but also remodel the tumor microenvironment. Additionally, the company is developing antibodies designed to block the activation of specific HLA molecules associated with autoimmune conditions. Through its innovative approach, ImmunOs Therapeutics seeks to improve the lives of patients suffering from serious diseases.
Onward
Post in 2024
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).
Onera Health
Series C in 2024
Onera Health, Inc. specializes in providing innovative sleep diagnostic solutions and services aimed at identifying sleep disorders such as insomnia, sleep apnea, and narcolepsy. Founded in 2017 and headquartered in Palo Alto, California, with a research and development office in Eindhoven, the Netherlands, Onera Health has developed advanced sleep diagnostic patch systems that collect and analyze sleep data. These systems not only enhance the diagnosis of sleep-related ailments but also have potential applications in monitoring various chronic health conditions. By delivering comprehensive sleep test data to healthcare providers, Onera Health aims to improve patient care and reduce healthcare costs, ultimately enhancing the health and quality of life for individuals globally.
ERS
Private Equity Round in 2023
ERS electronic GmbH is a manufacturer based in Munich, Germany, specializing in thermal wafer chuck systems for the semiconductor industry. Established in 1970, the company designs and produces a range of thermal solutions tailored for various testing applications. Its product lineup includes the AirCool3 modular chuck system, the PowerSense chuck system for high-wattage logic chips, and the WaferTherm chuck system for laboratory thermal testing. Additionally, ERS offers the AirCool3 Package Level thermal system for testing packaged devices and Aircool AC3 chucks for wafer temperature probing. The company is also capable of developing custom solutions to address specific thermal testing and processing challenges within the industry.
Witec
Acquisition in 2023
Witec is a Contract Design Manufacturer of high-tech equipment and high-end products.
Complement Therapeutics
Series A in 2023
Complement Therapeutics is a preclinical stage biotechnology company focused on developing a precision medicine diagnostic platform to address chronic diseases associated with the dysregulation of the complement system. The company's innovative platform enables the stratification of patients based on their complement-activation profiles, which has the potential to enhance patient selection for clinical trials and serve as an efficacy biomarker in future studies. By offering a more tailored approach to treatment, Complement Therapeutics aims to improve medical outcomes for patients suffering from these chronic conditions.
Mediar Therapeutics
Series A in 2023
Mediar Therapeutics is a pre-clinical stage biotechnology company based in Cambridge, Massachusetts, focused on developing antibody-based therapeutics for the treatment of fibrosis. Founded in 2019, the company aims to provide innovative solutions by targeting key fibrotic mediator proteins that contribute to the development of fibrosis in chronically damaged organs. Through its research and development efforts, Mediar seeks to enable medical practitioners to halt and potentially reverse critical fibrosis and related conditions, addressing a significant unmet need in the field of fibrotic diseases.
Fire1
Venture Round in 2023
Fire1, based in Dublin, Ireland, is dedicated to developing innovative therapeutic devices aimed at enhancing the lives of heart failure patients. The company has created a remote monitoring system that allows healthcare providers to access real-time patient data and insights. This technology facilitates the early detection of complications associated with heart failure, enabling proactive interventions that can lead to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to address critical challenges in heart failure management and contribute to better healthcare solutions.
Paleo
Series A in 2023
Paleo is a food ingredient company focused on developing innovative, animal-free heme proteins for plant-based meat and fish alternatives. Utilizing precision fermentation, Paleo produces bio-identical heme proteins that are non-GMO and replicate the sensory and nutritional qualities of their animal-derived counterparts. This technology allows businesses to create sustainable food products that not only taste and feel like real meat or fish but also align with ethical considerations by avoiding harm to animals. Through its commitment to bioscience, Paleo aims to enhance the flavor and appeal of plant-based foods, contributing to a healthier and more sustainable food system.
JenaValve Technology
Series C in 2022
JenaValve Technology, Inc., established in 2006, specializes in developing and manufacturing transcatheter aortic valve replacement (TAVR) systems. Its flagship product, the Trilogy™ Heart Valve System, is designed to treat high-risk patients with symptomatic, severe aortic regurgitation and aortic stenosis. The system, which received CE Mark approval in 2021, features a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame with integral locators that engage with the native valve cusps. JenaValve operates globally, with headquarters in Irvine, California, and additional locations in Munich, Germany, and Leeds, United Kingdom.
ImCheck Therapeutics
Series C in 2022
ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.
ImmunOs Therapeutics
Series B in 2022
ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of novel human immunomodulatory proteins aimed at enhancing cancer treatment and addressing autoimmune diseases. By focusing on next-generation therapeutics, ImmunOs aims to create drugs that not only exhibit direct anti-tumor effects but also remodel the tumor microenvironment. Additionally, the company is developing antibodies designed to block the activation of specific HLA molecules associated with autoimmune conditions. Through its innovative approach, ImmunOs Therapeutics seeks to improve the lives of patients suffering from serious diseases.
Variass
Acquisition in 2022
Variass is a specialist in Electronic Manufacturing Services (EMS) and system supply, primarily serving the defense, medical, water, and industrial sectors. The company develops and produces client-specific electronic and mechatronic products and systems, emphasizing small to medium production runs characterized by high variability and complexity. Variass offers a comprehensive range of services, including product and process development, industrialization, series production and assembly, as well as logistics and lifecycle management. This approach ensures reliable delivery and flexibility, meeting the diverse needs of its clients in various demanding markets.
BioConnection
Secondary Market in 2022
BioConnection is a European company specializing in the development and manufacturing of injectable biopharmaceutical products. It offers contract manufacturing services to small biopharmaceutical companies, providing access to both small-scale clinical batch production and large-scale commercial manufacturing facilities. The company is equipped with filling and freeze-drying technology and supports clients with sterile drug product development, process validation, and analytical services. BioConnection's extensive network of skilled suppliers and collaborators, including partnerships with experienced organizations, enhances its ability to deliver reliable solutions for clients focusing on personalized medications and clinical trials. By serving as an independent intermediary, BioConnection simplifies the process for companies that may lack the resources or expertise for comprehensive clinical development, ensuring efficient product delivery without the need for clients to seek multiple vendors.
Precirix
Series B in 2022
Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.
GSDI
Acquisition in 2022
GSDI Group specializes in the surface treatment and installation of technical adhesive films, providing comprehensive solutions for renovation, thermal comfort, protection, and decoration. The company serves clients across various sectors, including railway, building, and food. GSDI is distinguished by its extensive installation capabilities in Europe, employing 160 trained applicators who have completed training at the company's approved center. In addition to adhesive films, GSDI offers a range of products such as tarpaulins and varnishes, addressing the diverse needs and challenges faced by its customers in urban cosmetic services.
Topas Therapeutics
Series B in 2021
Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological capabilities. Its lead product candidate, TPM203, is currently undergoing clinical testing for pemphigus vulgaris, an orphan disease. Additional programs are being developed for conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. Topas Therapeutics has established research and collaboration agreements with notable partners, including Eli Lilly and Company and Boehringer Ingelheim, to advance its innovative approaches to immune tolerance. The company aims to address significant unmet medical needs by promoting immune tolerance to blood-borne antigens.
Klotter
Private Equity Round in 2021
Klotter specializes in the fields of energy technology, automation technology, lightning technology, and building technology.
Onward
Venture Round in 2021
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).
Verkley
Acquisition in 2021
Verkley is a company focused on constructing and maintaining underground cable and pipeline networks for various sectors, including energy, water, telecommunications, and industrial applications. It provides a range of services, including the laying, mounting, and testing of cables and pipes for gas, water, electricity, heating networks, and public lighting. By leveraging its expertise, Verkley assists clients in optimizing their infrastructure while minimizing waste and reducing environmental impact. The company serves a diverse clientele that includes network companies, industrial firms, and government entities.
Sofatutor
Venture Round in 2021
Sofatutor GmbH is an educational technology company based in Berlin, Germany, that operates an online learning platform tailored for K-12 students in Europe. Founded in 2008, Sofatutor provides a comprehensive range of resources, including video lessons, practice exercises, worksheets, and homework assistance, covering subjects such as mathematics, physics, English, and chemistry, among others. The platform is designed to support students, teachers, and parents, offering tools that facilitate learning and exam preparation. By providing short video tutorials and personalized tutoring sessions, Sofatutor aims to enhance students' academic performance and foster independent learning. The service is accessible to users in Germany and internationally, catering to a diverse audience of learners.
Kinaset Therapeutics
Series A in 2020
Kinaset Therapeutics is a therapeutics company dedicated to developing innovative drugs aimed at addressing unmet medical needs, particularly in the field of respiratory health. The company focuses on creating novel therapeutics for patients suffering from intractable diseases, including severe asthma. Kinaset Therapeutics is advancing its lead asset, which employs a unique approach to treating severe asthma, thereby offering healthcare providers a less invasive and more cost-effective treatment option. Through its efforts, Kinaset Therapeutics aims to make a significant positive impact on the lives of individuals affected by challenging respiratory conditions.
SynOx Therapeutics
Series A in 2020
SynOx Therapeutics is a clinical-stage biopharmaceutical company based in Dublin, Ireland, that specializes in the development of innovative therapies for cancer. The company's primary focus is on emactuzumab, a humanized monoclonal antibody targeting CSF-1R, aimed at depleting macrophages within tumor tissues. This therapy is being investigated for its potential in treating diffuse tenosynovial giant cell tumors and other macrophage-mediated diseases. Established in 2019, SynOx Therapeutics is backed by experienced investors in the biopharmaceutical field, emphasizing its commitment to addressing the unmet clinical needs of patients and improving their quality of life through advanced treatment options.
Topas Therapeutics
Series B in 2020
Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological capabilities. Its lead product candidate, TPM203, is currently undergoing clinical testing for pemphigus vulgaris, an orphan disease. Additional programs are being developed for conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. Topas Therapeutics has established research and collaboration agreements with notable partners, including Eli Lilly and Company and Boehringer Ingelheim, to advance its innovative approaches to immune tolerance. The company aims to address significant unmet medical needs by promoting immune tolerance to blood-borne antigens.
Televic
Acquisition in 2020
Televic specializes in providing advanced communication systems tailored for specific markets, including healthcare, education, railways, and conferences. The company manufactures a range of products such as digital on-board services networks, passenger information systems, visual information solutions, rail information systems, and entertainment systems. These offerings ensure seamless and interference-free communication, enhancing user experience in various settings. Televic's commitment to high-tech and high-quality solutions positions it as a leader in its sector, while its strategy to diversify shareholding aims to support further global expansion and strengthen its market presence.
AME
Private Equity Round in 2020
AME is an independent developer and manufacturer of high quality electronic products located in the top technological region.
JenaValve Technology
Series D in 2020
JenaValve Technology, Inc., established in 2006, specializes in developing and manufacturing transcatheter aortic valve replacement (TAVR) systems. Its flagship product, the Trilogy™ Heart Valve System, is designed to treat high-risk patients with symptomatic, severe aortic regurgitation and aortic stenosis. The system, which received CE Mark approval in 2021, features a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame with integral locators that engage with the native valve cusps. JenaValve operates globally, with headquarters in Irvine, California, and additional locations in Munich, Germany, and Leeds, United Kingdom.
General Fusion
Series E in 2019
General Fusion Inc. is a Canadian company focused on the development of commercial Magnetized Target Fusion (MTF), a promising hybrid approach that combines elements of magnetic fusion and inertial confinement fusion. Founded in 2002 and based in Burnaby, the company aims to create utility-scale fusion power plants that can provide clean, safe, and abundant energy. General Fusion is pioneering a patent-pending concept that leverages advancements in MTF, which has seen limited exploration since the 1970s. The company is dedicated to demonstrating and commercializing this innovative energy solution by the end of the decade. It is supported by a network of global energy venture capital firms, industry leaders, and technology innovators, all working to reduce technical risks and accelerate the path to viable fusion energy.
ImCheck Therapeutics
Series B in 2019
ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.
iSTAR Medical
Series C in 2019
iSTAR Medical SA is a Belgian company specializing in the development of innovative ophthalmic implants aimed at treating glaucoma. Founded in 2010 as a spinout of Healionics Corporation, the company has established a strong presence in the market with its flagship product, the STARflo glaucoma implant. This non-degradable, micro-porous drainage system reduces intraocular pressure in patients with open-angle glaucoma by enhancing the eye's natural uveoscleral outflow. iSTAR Medical also offers additional products, including STARflo PLUS and STARflo MINI, which provide surgical therapies for glaucoma. The implants are designed to integrate with surrounding tissue, exhibiting anti-fibrotic and anti-inflammatory properties, thereby minimizing complications and the need for medication. The company operates from its eco-friendly R&D and manufacturing facility in Belgium and distributes its products across various international markets, including Australia, China, France, Hungary, Italy, Poland, and Turkey. iSTAR Medical has received multiple quality certifications, including ISO 13485 and ISO 9001, and achieved CE Mark approval for its devices.
Biotalys
Series C in 2019
Biotalys NV is an agricultural technology company based in Ghent, Belgium, that specializes in the research and development of biopesticides aimed at controlling pests and diseases affecting crops and harvested products. The company utilizes its proprietary Agrobody technology platform to create protein-based crop protection solutions that effectively bind to leaves, seeds, and fruits, enabling targeted delivery of active ingredients. This innovative approach combines the performance of traditional chemical pesticides with the safety profile of biological alternatives, making Biotalys' products suitable for both pre- and post-harvest applications. Founded in 2013, Biotalys is committed to providing sustainable and safe food protection solutions, positioning itself as a leader in the evolution of agricultural practices.
Alro Group
Acquisition in 2019
The Alro Group is a leading provider of coating services for the automotive industry, headquartered in Dilsen-Stokkem, Belgium. With a significant presence in Western and Central Europe, the company has evolved from a small operation into a reputable group specializing in various coating techniques. Alro Group offers a range of services including wet coating, electrocoating, powder coating, and assembly, allowing clients to obtain tailored metal and plastic products that meet their specific needs.
Smart Battery Solutions
Acquisition in 2019
Smart Battery Solutions GmbH, founded in 2010 and based in Kleinostheim, Germany, specializes in the development and manufacturing of lithium-ion battery systems and charging technologies. The company focuses on the low voltage segment, producing a range of products including energy storage systems, chargers, and batteries suitable for various applications. Their offerings cater to the e-mobility sector, serving industries such as e-bikes, e-scooters, watercraft, and drones. Additionally, Smart Battery Solutions provides stationary energy solutions for constant power supply devices, targeting markets in energy production, robotics, nautical science, and healthcare.
Precirix
Series A in 2018
Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.
La Comtoise
Acquisition in 2018
La Comtoise specializes in developing and supplying customized cheese solutions for the food service industry. The company offers a diverse range of processed cheese products that maintain consistent physicochemical and organoleptic qualities. These products are designed to be integrated into various prepared foods, including breaded escalopes and grilled ham and cheese sandwiches, allowing clients to meet their specific culinary needs.
Medi-Markt Homecare-Service
Acquisition in 2018
Medi-Markt is the specialist for medical aids and care aids.
Medi Markt Service Nord Ost
Acquisition in 2018
Medi Markt Service Nord Ost is a provider of medical aids in Germany, specializing in incontinence care, diabetes management, stoma care, enteral nutrition, tracheostomy, and various dressing materials. With over a decade of experience, the company focuses on delivering tailored solutions that meet the specific needs of patients. Their offerings also include care products and hygiene and disinfection supplies, ensuring comprehensive support for individuals managing chronic health conditions. Medi Markt Service Nord Ost aims to empower patients by providing essential resources to help them navigate their health challenges effectively.
Kind Technologies
Venture Round in 2018
Kind Technologies is a horticulture automation company that focuses on serving greenhouse growers and packing centers. It specializes in developing systems for internal logistics, sorting, packing, and inspection, utilizing advanced technologies such as computer vision and robotics. By integrating these technologies, Kind Technologies enables its clients to enhance productivity, minimize waste, and manage the growth of fruits, vegetables, and plants more effectively. The company's solutions aim to support sustainable practices in agriculture, allowing for more predictable and efficient operations within the horticulture sector.
Laser 2000
Acquisition in 2018
Laser 2000 is an independent European supplier specializing in innovative laser and photonics solutions. With over 30 years of experience, the company offers a wide range of products, including lasers, light sources for material processing, measurement equipment, fiber optics, 3D imaging, optical power and energy meters, and cameras. Laser 2000 serves a diverse clientele, including prominent companies and research institutes in sectors such as automation and sensor technology, optical communications, biotech and medicine, automotive, and aerospace. The company's long-standing relationships with customers and suppliers position it as a pioneer in the photonics industry, enabling it to provide tailored consulting and a comprehensive product portfolio for optical technologies.
Impact
Acquisition in 2018
Impact is a temporary employment agency for specialists in technics, construction and office work. IMPACT is a specialized temporary employment agency with its headquarters in Hasselt. Their main objective? By means of a personal approach, a clear focus, and a great deal of engagement and expertise, they aim to match employers with specialists who are looking for a job in the fields of technics, construction, or office work. Thus, they contribute to the successful growth of enterprises and to the professional satisfaction of the experts who found a job thanks to them.
France Thermes
Acquisition in 2018
France Thermes is an organization that oversees various subsidiaries focused on the hydrotherapy industry. It manages thermal resorts in Bagnoles de l'Orne, located in Normandy, and Châtel-Guyon in Auvergne, both of which have been under its supervision since January 1, 2017. The company specializes in therapeutic treatments utilizing natural thermal sources, offering water-based therapies designed to address conditions such as osteoarthritis and rheumatism. Through its healthcare spas and facilities, France Thermes aims to promote a healthy lifestyle for its patients by providing comprehensive therapeutic services in a serene environment.
Fire1
Series C in 2018
Fire1, based in Dublin, Ireland, is dedicated to developing innovative therapeutic devices aimed at enhancing the lives of heart failure patients. The company has created a remote monitoring system that allows healthcare providers to access real-time patient data and insights. This technology facilitates the early detection of complications associated with heart failure, enabling proactive interventions that can lead to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to address critical challenges in heart failure management and contribute to better healthcare solutions.
Stiplastics S.A.S.
Venture Round in 2018
Stiplastics S.A.S. specializes in the design, development, and manufacturing of medical devices for the healthcare sector, both in France and internationally. Established in 1985 and headquartered in Beauvoir-en-Royans, the company offers a diverse range of products, including distributor pumps, tamper-proof containers, caps, closures, cosmetic spatulas, nozzles, droppers, measuring scoops, and various packaging solutions. Additionally, it provides pharmaceutical packaging products, carrying cases for biological samples, and pillboxes. Stiplastics S.A.S. distributes its offerings through a comprehensive catalog, catering to the needs of the healthcare industry.
Wemas Absperrtechnik
Acquisition in 2017
Wemas Absperrtechnik is a leading manufacturer in Germany specializing in integrated and certified solutions for road safety technology, primarily serving the infrastructure and construction markets. The company's extensive product lineup includes road shut-off devices such as safety barriers, fall arrestors, lights, footplates, and traffic cones. In addition to its core offerings, Wemas also produces various plastic products, including mortar baths, protective devices for the logistics sector, and equipment for equestrian sports. With a dedicated workforce of over 120 employees at its headquarters in Gütersloh, Wemas focuses on delivering high-quality products to wholesalers and service providers, ensuring traffic safety and customer satisfaction.
Cegeka
Venture Round in 2017
Cegeka is an information technology company that specializes in providing cloud computing, software development, cybersecurity, and digital transformation services. The company aims to assist businesses in navigating the complexities of the digital landscape by offering a range of solutions, including application management, data solutions, and digital workplace services. Cegeka's offerings are designed to enhance operational efficiency and competitive advantage, helping clients integrate digital tools for improved collaboration and streamlined processes. By focusing on these core services, Cegeka supports organizations in their efforts to thrive in an increasingly digital world.
Arseus Medical Group
Private Equity Round in 2017
Arseus Medical is a distributor of medical equipment and consumables focused on serving hospitals, specialists, nursing homes, and home healthcare providers. The company emphasizes efficient diagnostic and therapeutic solutions, offering a range of products including sterile medical gloves, incontinence materials, wound care items, and small instruments. Arseus Medical supports healthcare professionals with systems for patient monitoring and treatment in various care settings, both inside and outside hospitals. By providing innovative solutions and high-quality resources, the company aims to enhance the efficiency and effectiveness of medical practices, allowing professionals to concentrate on patient care. With a strong presence in the Benelux region and dedicated teams, Arseus Medical distinguishes itself through exclusive distribution agreements and a commitment to delivering value to its clients.
MVZ Holding
Acquisition in 2017
MVZ Holding focusses on providing best in class primary medical care and has grown successfully by executing a disciplined expansion strategy. The company currently runs more than 25 medical practices in different regions in Switzerland and plans further expansion within the country.
ImCheck Therapeutics
Series A in 2017
ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.
ALT Technologies
Acquisition in 2017
ALT Technologies, established in 1935, is a prominent manufacturer of critical airbag components, specializing in covers, wraps, and seals. The company serves nearly all major airbag producers, securing multi-annual contracts that ensure its products are integrated into a wide range of well-known automobile brands globally. In addition to its airbag component production, ALT Technologies also produces tailor-made die-cut and self-adhesive products for various sectors, including automotive and durable goods. The company utilizes materials such as stainless steel and non-woven plastics to deliver innovative and cost-effective solutions that address evolving customer needs in developing new product lines.
Biotalys
Series B in 2017
Biotalys NV is an agricultural technology company based in Ghent, Belgium, that specializes in the research and development of biopesticides aimed at controlling pests and diseases affecting crops and harvested products. The company utilizes its proprietary Agrobody technology platform to create protein-based crop protection solutions that effectively bind to leaves, seeds, and fruits, enabling targeted delivery of active ingredients. This innovative approach combines the performance of traditional chemical pesticides with the safety profile of biological alternatives, making Biotalys' products suitable for both pre- and post-harvest applications. Founded in 2013, Biotalys is committed to providing sustainable and safe food protection solutions, positioning itself as a leader in the evolution of agricultural practices.
Breath Therapeutics
Series A in 2017
Breath Therapeutics GmbH, based in Munich, Germany, with an additional office in Menlo Park, California, specializes in the development of drug-aerosol therapeutics aimed at treating bronchiolitis obliterans syndrome and other severe respiratory diseases. Founded in 2016, the company operates as a subsidiary of Zambon S.p.A. Breath Therapeutics focuses on innovative inhalation therapies that combine novel formulations of existing drugs with advanced inhalation technology, specifically targeting rare respiratory conditions with significant unmet medical needs. Their product offerings include a liposomal formulation of cyclosporine A for inhalation, delivered via a high-performance nebulizer that enhances drug concentration in the lungs while reducing systemic exposure. This approach aims to improve treatment efficacy and safety for patients suffering from life-threatening pulmonary diseases.
Itineris
Venture Round in 2017
Itineris is a company that specializes in developing and implementing UMAX, a cloud-based customer information and customer relationship management solution tailored for the utilities sector. UMAX utilizes workflow automation and artificial intelligence to manage various aspects of utility operations, including meter reading, revenue collection, asset management, complex rate structures, and customer engagement initiatives. Built on the Microsoft Dynamics 365 platform and delivered through the Microsoft Azure Cloud, UMAX enhances operational efficiency and supports advanced customer engagement. Founded in 2003, Itineris has established a strong track record in software implementation, serving a diverse client base that includes notable organizations such as De Watergroep in Belgium, Eneco in the Netherlands, and the New York Department of Environmental Protection in the United States. The company's solutions are designed to empower utility professionals to navigate the evolving landscape of energy and water management effectively.
MEGA International
Private Equity Round in 2016
MEGA International specializes in providing digital transformation software and consulting services aimed at helping organizations manage enterprise complexity. In an era characterized by rapid market changes and evolving regulatory demands, the company offers a comprehensive suite of solutions that empower managers to make informed decisions regarding governance, innovation, cost optimization, and risk management. Their flagship product, HOPEX, integrates various software solutions to assist clients in overcoming corporate governance challenges and executing effective IT strategies and digital transformation initiatives. MEGA International is committed to enhancing business and IT agility for its customers, supported by consulting services recognized for their effectiveness. With a loyal clientele that spans over 40 countries, the company prioritizes customer success as a key driver of its innovation and business strategies.
Acceo
Acquisition in 2016
ACCEO operates in various sectors, primarily focusing on engineering, inspection, and certification services for buildings and large structures. The company specializes in elevator engineering and offers inspection and monitoring services for vertical transportation systems. Additionally, it conducts regulated accessibility audits and energy efficiency assessments for building owners, designers, and property managers, particularly in the commercial and administrative sectors. By providing expert advice on elevator design for both new and existing buildings, ACCEO assists its clients in enhancing the performance of their properties, reducing operational costs, and increasing overall property value. The company's services extend to the hospital market, ensuring compliance with accessibility standards and promoting energy efficiency.
spineart
Venture Round in 2016
Spineart Geneva SA is a medical device company based in Geneva, Switzerland, specializing in innovative solutions for spine surgery. Founded in 2005, the company provides a comprehensive range of sterile packed implants and compact instrument sets designed for minimally invasive surgical procedures, motion preservation, fusion, biologics, and fracture treatments. Its product offerings include various types of pedicle screws, cervical plates, interbody devices, and motion devices such as disc prostheses. Additionally, Spineart develops biologics devices like synthetic osteoconductive gels and scaffolds. By introducing patented and clinically validated technologies, the company aims to enhance the efficiency and safety of surgical practices for spine surgeons and operating room teams, ultimately benefiting patients.
Summa
Acquisition in 2016
Summa is a Belgian company established in 1973, initially focused on assembling high-tech recording devices for precision optical lenses. The company transitioned into the vinyl imaging sector in 1987 by modifying pen-plotters for vinyl-cutting applications. Today, Summa is recognized as a global leader in the manufacturing of digital roll cutters and cutting equipment tailored for the printing and graphic design industry. Its product offerings include cutters, flatbed cutter systems, and finishing systems, which are designed to help clients optimize workflows and reduce human error, ultimately saving time and resources. Summa serves various markets, including signage, outdoor advertising, and aerospace.
Riaktr (formely Real Impact Analytics)
Series A in 2016
Riaktr is a Belgian scale-up founded in 2009 and backed by first class investors (Fortino, Endeit, GIMV). We started as a service company under the name ‘Real Impact Analytics’. At the time, Big Data was the new big thing, driving important corporate investments. Yet, too often such investments were not yielding the desired returns. Since day one, we pursue a clear mission: leverage the value of telecom data. We do this by starting from the field to build user-centric frameworks driving results. We resist the ‘black box’ principle by putting data at the service of human intelligence and bringing teams together under a collaborative approach. Our brand Riaktr, adopted in 2018, symbolizes our pivot from a services business to a product company. Today our software products address two major questions faced by telcos: - How can I optimize my network CAPEX investments? - How can I optimize my Sales & Distribution operations? Behind the scenes, we are a team of computer scientists, engineers and business consultants based in the heart of Brussels, with a local presence close to our clients in South-Africa and Brazil. We have worked in many countries in Africa, Latin America, the Caribbean and Europe. We work with six of the ten biggest telecom groups to revolutionize the telecom and Consumer Goods industries.
EndoStim
Series D in 2016
EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.
Joolz
Private Equity Round in 2016
Joolz is a Netherlands-based company that specializes in the design and manufacture of premium pushchairs. Known for their award-winning products, Joolz emphasizes quality and ergonomic design, creating stylish and distinctive strollers that cater to the needs of both children and parents. The company's offerings include features such as detachable cradles, hypoallergenic mattresses, and four-wheel suspension, ensuring durability and ease of use for consumers. Joolz is committed to promoting a sustainable and healthy lifestyle for young families, which is evident in their use of reusable packaging and initiatives like the Joolz Birth Forest. Through their innovative products and focus on sustainability, Joolz aims to inspire families to enjoy a positive and enriching life.
Onward
Series A in 2016
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).
Topas Therapeutics
Series A in 2016
Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological capabilities. Its lead product candidate, TPM203, is currently undergoing clinical testing for pemphigus vulgaris, an orphan disease. Additional programs are being developed for conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. Topas Therapeutics has established research and collaboration agreements with notable partners, including Eli Lilly and Company and Boehringer Ingelheim, to advance its innovative approaches to immune tolerance. The company aims to address significant unmet medical needs by promoting immune tolerance to blood-borne antigens.
Contraload
Private Equity Round in 2016
Contraload is a rapidly expanding company based in Belgium, specializing in the pooling and rental of plastic pallets and containers. With over a decade of experience, the company manages nearly one million assets that are actively utilized across Europe. Contraload offers a diverse range of plastic pallets and intermediate bulk containers (IBCs) tailored to various supply chains, particularly in the food and fast-moving consumer goods (FMCG) sectors. The company serves prominent global clients such as Unilever and Nestle, addressing their stringent quality and hygiene standards while minimizing the risk of foreign body contamination. By providing cost-effective solutions, Contraload enables businesses to connect efficiently with suppliers and customers, allowing them to concentrate on their core operations.
Itho Daalderop
Acquisition in 2016
Itho Daalderop Group B.V. is a Netherlands-based company specializing in the development, manufacturing, and marketing of HVAC products for the residential sector. Founded in 1880 and operating as a subsidiary of Klimaatgarant B.V., the company offers a wide range of products including central heating systems, heat pumps, solar boilers, kitchen boilers, and ventilation systems. Itho Daalderop is dedicated to providing innovative solutions that ensure a healthy, comfortable, energy-efficient, and affordable indoor climate. The company also serves as an advisory partner to governments, corporations, and construction firms, supporting them in new construction, renovation, and replacement projects. With its headquarters in Schiedam and additional locations in Etten-Leur, Tiel, the United Kingdom, and Sint-Niklaas, Belgium, Itho Daalderop continues to expand its reach both domestically and internationally.
Legallais
Private Equity Round in 2016
Legallais is a prominent distributor of hardware and building products, specializing in ironmongery, plumbing, and electrical supplies. Primarily serving the French market, the company offers a comprehensive and high-quality range of products tailored for craftsmen, building operators, and maintenance companies. Renowned for its exceptional customer service, Legallais provides multiple ordering options, including mobile, online, and mail, ensuring convenience for its clients. The company also boasts automated logistics that facilitate prompt delivery, typically within 24 hours.
Brakel
Acquisition in 2015
Brakel has been market leader in the area of daylight access, fire safety and ventilation solutions for more than 35 years, with sales in both Europe and further afield. And we offer integral solutions for all kinds of building types comprising: Daylight Skylights, rooflights, skylights and facades Fire safety SHEV systems, fire alarm systems, detection, compartmentation Ventilation Natural ventilation, controlled natural ventilation Maintenance SHEV and ventilation systems, fire alarm systems, glass constructions
Equipe Zorgbedrijven Nederland
Private Equity Round in 2015
Equipe Zorgbedrijven Holding B.V. is a healthcare service organization based in Eindhoven, the Netherlands, specializing in the operation of clinics for specialized surgery. The company manages a network of clinics, providing focused medical services to meet the needs of patients in the region.
Biom'Up
Series C in 2015
Biom'Up S.A. is a French company based in Saint-Priest that specializes in the development and commercialization of hemostatic products utilizing patented biopolymers and collagen technology. Established in 2005, Biom'Up designs, manufactures, and sells innovative medical devices that enhance surgical practices across various specialties, including orthopedic, spinal, cardiac, general, maxillofacial, and laparoscopic surgeries. Their flagship products, HEMOBLAST bellows and associated laparoscopic applicators, aim to simplify surgical procedures and improve patient outcomes by facilitating guided regeneration of soft tissues and bone. The company markets its offerings primarily in Europe and the United States.
JenaValve Technology
Series C in 2015
JenaValve Technology, Inc., established in 2006, specializes in developing and manufacturing transcatheter aortic valve replacement (TAVR) systems. Its flagship product, the Trilogy™ Heart Valve System, is designed to treat high-risk patients with symptomatic, severe aortic regurgitation and aortic stenosis. The system, which received CE Mark approval in 2021, features a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame with integral locators that engage with the native valve cusps. JenaValve operates globally, with headquarters in Irvine, California, and additional locations in Munich, Germany, and Leeds, United Kingdom.
CoScale
Venture Round in 2015
CoScale offers a comprehensive performance monitoring platform tailored for production environments, focusing on servers, containers, and applications. The platform provides continuous monitoring and assesses the impact of performance on user experience and essential business metrics. By utilizing automated anomaly detection and contextual insights, CoScale enables proactive management of performance fluctuations that could affect financial outcomes. Its user base includes DevOps engineers, application owners, and business managers, all seeking to enhance digital performance through faster and more reliable websites and applications. This leads to improved user experiences and increased conversion rates, positioning CoScale as a valuable tool for organizations aiming to optimize their digital infrastructure.
Itineris
Venture Round in 2015
Itineris is a company that specializes in developing and implementing UMAX, a cloud-based customer information and customer relationship management solution tailored for the utilities sector. UMAX utilizes workflow automation and artificial intelligence to manage various aspects of utility operations, including meter reading, revenue collection, asset management, complex rate structures, and customer engagement initiatives. Built on the Microsoft Dynamics 365 platform and delivered through the Microsoft Azure Cloud, UMAX enhances operational efficiency and supports advanced customer engagement. Founded in 2003, Itineris has established a strong track record in software implementation, serving a diverse client base that includes notable organizations such as De Watergroep in Belgium, Eneco in the Netherlands, and the New York Department of Environmental Protection in the United States. The company's solutions are designed to empower utility professionals to navigate the evolving landscape of energy and water management effectively.
United Dutch Breweries
Acquisition in 2015
United Dutch Breweries B.V., based in Breda, the Netherlands, is an independent beer group that produces and supplies a diverse range of beer and malt-based beverages. Established in 1968, the company offers various products including lagers, non-alcoholic malt beverages, dark malt beverages, ciders, and specialty beers such as stouts. It operates under several heritage brands, including Oranjeboom, 3 Horses, Royal Dutch, and Atlas, which reflect the company's rich history. United Dutch Breweries distributes its products globally through both on-trade and off-trade channels, providing consumers access to a wide selection of freshly brewed beers at competitive prices. As a former subsidiary of Anheuser-Busch InBev SA/NV, the company has established itself as a key player in the beer industry.
Teads
Series B in 2015
Teads, Inc. is a company that specializes in creating enterprise software for digital branding, primarily through its video advertising supply side platform (SSP) designed for publishers and brands. Founded in 2012 and headquartered in New York, with additional offices in Chicago and California, Teads enables clients to generate outstream video advertising inventory and effectively monetize it via their sales forces, third parties, and programmatic buying. The platform offers an omnichannel solution for programmatic digital advertising across a global network of premium media, integrating technologies for buy-side, sell-side, creative, and data optimization. By providing brand-safe and engaging ad experiences, Teads reaches billions of unique users, enhancing the effectiveness of digital advertising transactions and delivering sustainable business outcomes for advertisers and agencies.
EcoChem International
Acquisition in 2014
EcoChem International is a manufacturer and distributor of eco-friendly flame retardant additives, primarily serving the building and construction, transportation, and electronic sectors. The company's products are incorporated into materials such as wood, insulation, textiles, and plastics to inhibit, suppress, or delay flame and smoke production in the event of a fire. Headquartered in Olen, Belgium, EcoChem operates production facilities in Willebroek, Belgium, and Offenbach, Germany, and caters to clients across 25 countries. By offering economically viable solutions that prioritize environmental protection, EcoChem aims to meet the growing demand for sustainable fire safety products.
Well Services Group
Private Equity Round in 2014
Well Services Group is a comprehensive service provider for the oil and gas industry, catering to both onshore and offshore operations. The company focuses on cleaning and regenerating existing oil and gas wells through the use of coiled tubing. Additionally, it offers installation services for plugs and measurement equipment within these wells. Well Services Group is committed to delivering high-quality services efficiently, utilizing state-of-the-art equipment and a team of experienced personnel. Its flexible operational approach allows for quick responses to customer needs across the petrochemical and energy sectors.
Mackevision Medien
Acquisition in 2014
Mackevision Medien Design GmbH, based in Stuttgart, Germany, is a leading provider of Computer Generated Imagery (CGI) and related services. The company specializes in data-driven 3D visualization, animation, and visual effects, offering high-quality image and film production as well as interactive applications. Mackevision's expertise covers a wide range of uses, including online product configurators, digital and print catalogs, virtual showrooms, point-of-sale kiosks, and augmented and virtual reality experiences. Additionally, the company engages in post-production services for broadcast videos and feature films, managing the entire CGI workflow from data preparation to creative design and final output.
Melijoe
Venture Round in 2014
Launched in 2007 by entrepreneur and mother of five Nathalie Christen-Genty, MELIJOE.COM is the world’s premier online fashion e-tailer for children ages 0-16. Featuring the latest in childrenswear trends inspired directly by adult runways, MELIJOE.COM is home to some of the industry’s most sought-after labels in kid’s fashion. MELIJOE.COM is above all an international brand, featuring 100% authentic products, speedy worldwide shipping and a website translated in six languages. Thanks to a developed editorial strategy and magazine-inspired web layout, MELIJOE.COM doubles as a digital news outlet for children’s fashion with Le Magazine, and between exclusive shopping edits, childrenswear news, trend reports and in-house photo shoots, MELIJOE.COM is an extra-large world of digital fashion for the smallest of fashionistas.
Thinkstep
Series B in 2014
Thinkstep AG, established in 1991 and headquartered in Leinfelden-Echterdingen, Germany, specializes in sustainability software, data, and consulting services. It offers a suite of products including life cycle assessment tools, corporate sustainability solutions, energy management systems, and supply chain transparency platforms. Thinkstep serves over 2,000 clients worldwide, including 40% of the Fortune 500, helping them achieve operational excellence, product innovation, brand value, and regulatory compliance. With a global presence in 19 countries, the company operates as a subsidiary of Sphera Solutions, Inc.
Ablynx
Grant in 2014
Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies®, a unique class of therapeutic proteins derived from single-domain antibody fragments. These innovative proteins are designed to address a variety of serious human diseases, including inflammation, hematology, oncology, and pulmonary conditions. Currently, Ablynx has around 25 projects in its pipeline, with five Nanobodies in clinical development. By combining the advantages of traditional antibodies and small chemical molecules, Ablynx aims to provide new therapeutic options that can significantly improve patient care and outcomes.
JenaValve Technology
Series C in 2014
JenaValve Technology, Inc., established in 2006, specializes in developing and manufacturing transcatheter aortic valve replacement (TAVR) systems. Its flagship product, the Trilogy™ Heart Valve System, is designed to treat high-risk patients with symptomatic, severe aortic regurgitation and aortic stenosis. The system, which received CE Mark approval in 2021, features a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame with integral locators that engage with the native valve cusps. JenaValve operates globally, with headquarters in Irvine, California, and additional locations in Munich, Germany, and Leeds, United Kingdom.
Wolf Lingerie
Acquisition in 2014
Wolf Lingerie is a manufacturer specializing in women's lingerie, focusing on both its proprietary brands, which include Rosy, Sans-Complexe, Billet Doux, Oups, and Jardin Secret, and collections for major retailers and prestigious international brands. The company emphasizes the provision of fashionable and affordable lingerie, with a particular commitment to plus-size offerings. It prioritizes great support, quality finishings, and carefully selected fabrics and cuts, catering to the diverse needs of women in the fashion industry.
Transdev Group
Private Equity Round in 2013
Transdev is a public transportation operator that focuses on providing comprehensive and accessible mobility solutions. The company manages a variety of transport services, including bus networks, long-haul coaches, rail, marine transportation, and airport facilities. By offering multi-modal transport options, Transdev enhances the commuting experience for passengers, ensuring safety and comfort. The company's operations emphasize local decision-making and customer engagement, allowing it to respond effectively to the needs and expectations of its clients. Transdev also incorporates innovative features such as applications that combine different transport modes and contactless payment systems, thereby facilitating seamless travel. Supported by major shareholders, Transdev is committed to delivering high-quality services while continuously seeking improvements to enhance the overall passenger experience.
Covagen
Series B in 2013
Covagen is a biopharmaceutical company focused on developing innovative therapies for inflammatory diseases and cancer. The company specializes in creating bispecific FynomAbs by genetically fusing its proprietary Fynomer binding proteins to antibodies. This unique approach allows for the design of therapeutics with novel mechanisms of action and improved efficacy. Covagen's lead product, COVA322, is aimed at treating inflammatory conditions such as rheumatoid arthritis and psoriatic arthritis. The company was founded in 2007 as a spin-off from ETH Zurich and has established partnerships to enhance its drug development efforts, including a strategic collaboration with Mitsubishi Tanabe for the development of bispecific FynomAbs targeting specific disease-related pairs. A diverse group of investors supports Covagen’s initiatives, providing the necessary resources to advance its innovative therapeutic candidates.
Eurocept
Private Equity Round in 2013
Eurocept is a healthcare company based in Ankeveen, the Netherlands, founded in 2001 by CEO Mike van Woensel. The company specializes in the registration, marketing, distribution, and sale of specialty medicines across various fields, including anesthetics, psychiatry, urology, pediatrics, and infectious diseases through its Eurocept Pharmaceuticals division. Additionally, Eurocept Homecare offers medical specialist homecare services, focusing on outpatient medical technology for the administration of medicine and nutrition. Eurocept aims to simplify the treatment relationship between medical practitioners and patients, providing comprehensive services that encompass pharmacovigilance, hospital account management, and support for pharmaceutical companies in meeting their medicinal and nursing care needs.
Almaviva Santé
Private Equity Round in 2013
Almaviva Santé is a private hospital group based in Puyrucard, France, founded in 2007 and headquartered in Marseille. The company operates a network of hospitals and health care clinics, offering a wide range of medical and surgical treatments across various specialties, including orthopedics, ophthalmology, cardiology, and urology. Almaviva Santé is committed to providing comprehensive care that prioritizes both safety and comfort for its patients.
Endosense
Series C in 2013
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.
NovoPolymers
Private Equity Round in 2013
NovoPolymers NV is a company focused on developing and producing sustainable solutions for the photovoltaic market. It specializes in creating front and back encapsulants designed to protect solar cells, which enhance the power output of both crystalline silicon and thin-film solar modules. By optimizing these encapsulants, NovoPolymers aims to add value throughout the photovoltaic supply chain, contributing to the efficiency and sustainability of solar energy production.
JenaValve Technology
Series C in 2013
JenaValve Technology, Inc., established in 2006, specializes in developing and manufacturing transcatheter aortic valve replacement (TAVR) systems. Its flagship product, the Trilogy™ Heart Valve System, is designed to treat high-risk patients with symptomatic, severe aortic regurgitation and aortic stenosis. The system, which received CE Mark approval in 2021, features a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame with integral locators that engage with the native valve cusps. JenaValve operates globally, with headquarters in Irvine, California, and additional locations in Munich, Germany, and Leeds, United Kingdom.
Complix
Series B in 2013
Complix is a biopharmaceutical company dedicated to the discovery and development of Alphabodies™, a new class of therapeutics designed to target challenging disease targets. These Alphabodies™ exhibit high affinity for a variety of disease targets, particularly those that are difficult to access with traditional antibodies or other protein-based therapies. The unique stability and versatility of Alphabodies™ allow for alternative non-injectable delivery methods, enhancing their potential in therapeutic applications. The company's pipeline focuses on intracellular targets significant in cancer, autoimmunity, and viral diseases, aiming to combine the effectiveness of biologics with the cell-penetrating capabilities and stability characteristic of small molecules.
Luciad
Acquisition in 2013
Luciad specializes in high-performance geospatial software services designed to support mission-critical operations across various sectors. The company's applications enhance the capabilities of developers and end users through advanced visual analytics, enabling them to leverage real-time location intelligence. Luciad's tools facilitate the development of next-generation geospatial systems applicable in areas such as public safety, smart cities, and defense. By providing intuitive command and control systems, the company allows users to make informed decisions based on dynamic information. Additionally, Luciad offers software solutions that integrate data with geographical information, including maps, satellite imagery, and terrain elevation in multiple formats.
Marco Vasco
Series A in 2013
Marco Vasco is an online travel agency based in Paris, France, that specializes in organizing tailor-made journeys for clients seeking adventure and unique travel experiences. Founded in 2005, the company, previously known as Planetveo and Prestige Voyages, has established itself as a leader in the custom holiday market. Marco Vasco offers a wide range of travel services to diverse destinations across Asia, Africa, the Americas, Europe, and the Middle East. The agency is known for its personalized approach, providing clients with detailed itineraries, local guides, and comprehensive information on activities and accommodations. Since becoming profitable in 2010, Marco Vasco has experienced significant revenue growth, reflecting its successful adaptation to the demands of modern travelers. The company also has an office in Shanghai, China, further enhancing its international reach. As of 2017, Marco Vasco operates as a subsidiary of Société du Figaro, SAS.
Lampiris
Venture Round in 2013
Lampiris N.V., founded in 2003 and based in Liège, Belgium, is an independent supplier of electricity and gas, serving both private individuals and businesses. The company has been active in the Belgian energy market since 2005 and has established itself as the third-largest supplier in the residential sector, with over a million accounts. In addition to energy supply, Lampiris offers various energy services, including insulation, furnace maintenance, and heating solutions using wood and pellets, as well as smart thermostats. As of September 2016, Lampiris operates as a subsidiary of Elf Aquitaine S.A.
Multiplicom
Venture Round in 2013
Multiplicom specializes in the development of molecular diagnostics products aimed at medical genetics and clinical laboratory applications. The company manufactures molecular diagnostic kits that facilitate the collection of genetic information, enabling personalized treatment options for patients. These kits are particularly valuable for early identification of congenital defects during pregnancy, thereby supporting effective and affordable healthcare solutions. Through its innovative products, Multiplicom strives to enhance access to personalized medicine in the field of genetics.
McPhy Energy
Venture Round in 2013
McPhy Energy S.A. is a French cleantech company based in La Motte, established in 2008. It specializes in developing and supplying equipment for hydrogen production, storage, and distribution, catering to the hydrogen energy, zero-emission mobility, and industrial hydrogen markets globally. The company's product portfolio includes alkaline electrolyzers that facilitate hydrogen production in various capacities, as well as innovative solid-state hydrogen storage solutions. Additionally, McPhy designs and manufactures hydrogen refueling stations and integrated hydrogen solutions, positioning itself as a key player in the transition towards sustainable energy systems.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.